Healthcare
PTC Therapeutics, Inc. (PTCT)
Data as of July 17, 2026
Environment story
PTC Therapeutics discloses no quantified Scope 1, Scope 2, or Scope 3 greenhouse gas emissions in the 10-K filing. The company does not disclose a net-zero target date or any verified decarbonization initiatives. No carbon offset programs, renewable energy commitments, or climate-related controversies are mentioned. The company operates in rare disease biopharmaceuticals with no direct fossil-fuel exposure; however, environmental data transparency is minimal. Absence of disclosed environmental commitments and emissions metrics results in a moderately depressed score reflecting incomplete ESG disclosure rather than active harm.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
No disclosed initiatives on file for this pillar.
Social story
PTC Therapeutics does not disclose CEO-to-median-worker pay ratios, union standing, plant safety metrics, or detailed workforce turnover rates in the 10-K. No documented labor disputes, strikes, or union-suppression activities are identified. Leadership diversity metrics are not explicitly provided in the filing. The company has no disclosed supply-chain human-rights audits or flagged labor risks related to rare-disease pharmaceutical manufacturing. Absence of negative labor indicators and no major controversies support a moderate-to-good score; however, minimal proactive diversity and compensation transparency limits the rating.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Rare Disease Focus & Unmet Medical NeedCompany dedicates portfolio to rare disorder treatments, including orphan designations (Upstaza/Kebilidi, Waylivra). Mission emphasizes patient access to best-in-class treatments.Positive alignment with vulnerable patient populations; no direct labor or social-harm signal.
Governance story
PTC Therapeutics does not disclose board independence percentage, share structure details (single vs. dual-class), or annual lobbying expenditures in the 10-K. No antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed. No active litigation to block shareholder climate proposals is mentioned. The company discloses no material governance controversies or SEC consent decrees. Absence of red-flag governance issues supports a moderate score; however, lack of transparency on board composition, share voting structure, and political engagement limits the rating.
Criticisms on file
-
Translarna EEA Marketing Authorization Denial (March 2025): European Commission adopted CHMP negative opinion and did not renew conditional marketing authorization for Translarna (nmDMD). Material revenue risk for company.Source: PTCT 10-K, Item 1 Business, Translarna for treatment of nmDMD section
-
Vatiquinone NDA Complete Response Letter (August 2025): FDA issued complete response letter stating substantial evidence of efficacy was not demonstrated. Additional adequate and well-controlled study required for resubmission.Source: PTCT 10-K, Item 1 Business, Inflammation and Ferroptosis Platform section; Item 7 MD&A
Disclosed initiatives
-
Regulatory Compliance & Product DevelopmentCompany emphasizes adherence to FDA, EMA, and international regulatory pathways. Formal governance over clinical trial design, safety monitoring, and marketing authorization processes.Standard pharma governance; supports patient safety and regulatory credibility.
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of PTC Therapeutics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open PTC Therapeutics, Inc. in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics